XTL Biopharmaceuticals acquires 85% stake in NeuroNOS for autism therapeutics Jan 13, 2026 09:28AM
Beyond Air, Inc. (XAIR) subsidiary NeuroNOS appoints Dan Shechtman to SAB Apr 15, 2025 04:06PM
Beyond Air (XAIR) Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival i Oct 17, 2023 07:32AM
Beyond Air (XAIR) Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide in Combination with Checkpoint Inhibitor Therapy Oct 16, 2023 07:32AM
Beyond Air, Inc. (XAIR) Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy Apr 19, 2023 09:01AM


Jan 30, 2023 07:03AM Beyond Air, Inc. (XAIR) Appoints Gavin Choy as COO
Dec 13, 2022 09:26AM Beyond Air, Inc. (XAIR) Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide Induced a Systemic Response tha
Jun 1, 2022 07:03AM Beyond Air's (XAIR) Beyond Cancer Appoints Jedidiah Monson as Chief Medical Officer
Nov 4, 2021 07:33AM Beyond Air, Inc. (XAIR) Separates Cancer Business into Beyond Cancer